These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 19390552)

  • 21. Obstacles and opportunities in the clinical development of targeted therapeutics.
    Dy GK; Adjei AA
    Prog Drug Res; 2005; 63():19-41. PubMed ID: 16265875
    [No Abstract]   [Full Text] [Related]  

  • 22. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives.
    Seymour L
    Curr Pharm Des; 2002; 8(25):2279-84. PubMed ID: 12369856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.
    Le Tourneau C; Diéras V; Tresca P; Cacheux W; Paoletti X
    Target Oncol; 2010 Mar; 5(1):65-72. PubMed ID: 20361265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early oncology clinical trial design in the era of molecular-targeted agents.
    Brunetto AT; Kristeleit RS; de Bono JS
    Future Oncol; 2010 Aug; 6(8):1339-52. PubMed ID: 20799878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discrete event simulation applied to pediatric phase I oncology designs.
    Barrett J; Skolnik J; Jayaraman B; Patel D; Adamson P
    Clin Pharmacol Ther; 2008 Dec; 84(6):729-33. PubMed ID: 18923388
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?
    Hidalgo M
    Adv Exp Med Biol; 2008; 610():128-43. PubMed ID: 18593020
    [No Abstract]   [Full Text] [Related]  

  • 30. Innovations for phase I dose-finding designs in pediatric oncology clinical trials.
    Doussau A; Geoerger B; Jiménez I; Paoletti X
    Contemp Clin Trials; 2016 Mar; 47():217-27. PubMed ID: 26825023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing-Challenging the "more is better" dogma.
    Maués J; Loeser A; Cowden J; Johnson S; Carlson M; Lee S
    Clin Trials; 2024 Jun; 21(3):358-362. PubMed ID: 38385314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug development in oncology: classical cytotoxics and molecularly targeted agents.
    Kummar S; Gutierrez M; Doroshow JH; Murgo AJ
    Br J Clin Pharmacol; 2006 Jul; 62(1):15-26. PubMed ID: 16842375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs.
    Weber WA; Czernin J; Phelps ME; Herschman HR
    Nat Clin Pract Oncol; 2008 Jan; 5(1):44-54. PubMed ID: 18097456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Some notable properties of the standard oncology Phase I design.
    Hather GJ; Mackey H
    J Biopharm Stat; 2009; 19(3):543-55. PubMed ID: 19384695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DROID: dose-ranging approach to optimizing dose in oncology drug development.
    Guo B; Yuan Y
    Biometrics; 2023 Dec; 79(4):2907-2919. PubMed ID: 36807110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.
    Mandrekar SJ
    Am Soc Clin Oncol Educ Book; 2014; ():e107-10. PubMed ID: 24857087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
    Hazim A; Mills G; Prasad V; Haslam A; Chen EY
    J Natl Compr Canc Netw; 2020 Apr; 18(4):428-433. PubMed ID: 32259790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current stumbling blocks in oncology drug development.
    Gimmi CD
    Ernst Schering Res Found Workshop; 2007; (59):135-49. PubMed ID: 17117720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.
    Huang B; Bycott P; Talukder E
    J Biopharm Stat; 2017; 27(1):44-55. PubMed ID: 26882496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early phase cancer clinical trials: design, ethics and future directions.
    Coupe N; Gupta A; Lord SR
    Br J Hosp Med (Lond); 2015 Jul; 76(7):409-13. PubMed ID: 26140560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.